Viri in literatura:
a ESCEO - The European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases   – Evropsko združenje za klinične in ekonomske vidike zdravljenja osteoporoze, osteoartroze in mišično-skeletnih bolezni
b Symptomatic slow acting drugs for OA (SYSADOA) – simptomatska počasi delujoča zdravila za zdravljenje OA
1. Ripmeester, E. G. J. et al., 2018. Recent Insights into the Contribution of the Changing Hypertrophic Chondrocyte Phenotype in the Development and Progression of Osteoarthritis. Front. Bioeng. Biotechnol., 19 March 2018.
2. Nicholson, S. et al., 2009. Reducing Premature Osteoarthritis in the Adolescent Through Appropriate Screening. Journal of Pediatric Nursing, February 2009 Volume 24, Issue 1, Pages 69–74.
3. Akkiraju H, Nohe A. Role of Chondrocytes in Cartilage Formation, 2015. Progression of Osteoarthritis and Cartilage Regeneration. Journal of developmental biology. 2015;3(4):177-192.
4. Osteoarthritis of the knee (Gonarthrosis) Dostopno na: [07.04.2018]
5. Tani, K. et al, 2018. Physiotherapy Effects in Gait Speed in Patients with Knee Osteoarthritis. Open Access Maced J Med Sci. 2018 Mar 10;6(3):493-497.
6. Bruyère, O, 2014. An algorithm recommendation for the management of knee osteoarthritis in Europe and internationally: A report from a task force of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Seminars in Arthritis and Rheumatism 44 (2014) 253-263.
7. Kopčavar-Guček N. naravni izlečki v ambulanti zdravniške družinske medicine 2009
8. Product monography DONA
9. Persiani, S. et al, (2005). A Glucosamine oral bioavailability and plasma pharmacokinetics after increasing doses of crystalline glucosamine sulfate in man. Osteoarthritis Cartilage. 2005 Dec; 13(12): 1041-9
10. Reginster, J-YL et al., (2017). Different glucosamine sulfate products generate different outcomes on osteoarthritis symptoms. ARD Online First, September 6, 2017.
11. Saengnipanthkul, S. et al., (2017). Differentiation of patented crystalline glucosamine sulfate from other glucosamine preparations will optimize osteoarthritis treatment. International Journal of Rheumatic Diseases 2017.
12. Towheed, T.E., (2005): Glucosamine therapy for treating osteoarthritis. Cochrane Database Syst Rev. 2005 Apr 18;(2):CD002946.
13. Bruyere, O et al., (2008). Total joint replacement after glucosamine Sulphate treatment in knee osteoarthritis: results of a mean 8-year observation of patients from two previous 3-year, randomised, placebo-controlled trials. Osteoarthritis Cartilage. 2008; 16 (2): 254-60.
14. Runhaar, J et al., (2015). The role of diet and exercise and of glucosamine sulfate in the prevention of knee osteoarthritis: Further results from the Prevention of knee Osteoarthritis in Overweight Females (PROOF) study. Semin Arthritis Rheum. 2015 Nov 19.